

To: Members of the Dravet syndrome and DEE Patient Advocacy Communities

On Tuesday, January 7, 2025, Stoke announced that we have received alignment with global regulatory agencies related to the design of EMPEROR, our Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. This is an incredible achievement and one that wouldn't have been possible without each of you.

Since the announcement, we have been overwhelmed by the excitement and cannot wait to get the study up and running. We know that behind this excitement is a lot of urgency and I can assure you, we feel it too. Having the final protocol is the first step, but there is a lot of behind the scenes work that will need to take place as we coordinate with the clinical trial investigators and their teams to get the study up and running. We are doing everything we can to move quickly, and right now expect the study to start mid-2025.

The profound results we showed in our Phase 1/2 and ongoing OLE studies give us a lot of confidence as we enter Phase 3. EMPEROR is based on what we have learned from these studies and the invaluable input from you.


The EMPEROR study will evaluate the impact of zorevunersen on major motor seizure frequency compared to a sham injection in children and adolescents over the age of 2 and under the age of 18 with Dravet syndrome. We will also be evaluating improvements in multiple aspects of cognition and behavior based on what we have observed in our previous clinical studies. EMPEROR is unlike any study ever conducted in Dravet syndrome. It is going to be longer and more involved than studies of anti-seizure medicines, but the potential impacts of disease modification would be significant. We are pleased that the longer study design provides the opportunity to evaluate zorevunersen in a single study, and we were encouraged by discussions with regulators that reflected an understanding of the study's importance.

Through Stoke's Patient Advocacy, Clinical and Medical teams we will do our best to address your questions and appreciate your patience and understanding that there is a lot we can't answer just yet.

We know the community is counting on us and is eager for the study to start. We will continue to keep the community informed by showing up at congresses and continuing our regular interactions. In addition, we will be updating public information on clinicaltrials.gov and launching a website for EMPEROR in the coming months. In the meantime, we encourage you to visit the [Patients and Families section of our website](#) and follow us on LinkedIn and/ or X for the latest information and updates.

Again, thank you for all you do and for your ongoing feedback, support and trust.

Yours sincerely,

A handwritten signature in black ink that reads "Edward M. Kaye MD". The signature is written in a cursive, slightly slanted style.

Edward M. Kaye, MD
Chief Executive Officer and Director